(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 147.93% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Ocugen's revenue in 2025 is $5,370,000.On average, 7 Wall Street analysts forecast OCGN's revenue for 2025 to be $1,201,807,791, with the lowest OCGN revenue forecast at $873,559,353, and the highest OCGN revenue forecast at $1,770,855,035. On average, 7 Wall Street analysts forecast OCGN's revenue for 2026 to be $836,393,260, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $1,770,855,035.
In 2027, OCGN is forecast to generate $34,339,596,314 in revenue, with the lowest revenue forecast at $31,103,959,954 and the highest revenue forecast at $37,372,224,602.